TouchRESPIRATORY got the opportunity to catch up with Alyn Morice (University of Hull, Castle Hill Hospital, Yorkshire, UK) around the unmet needs and treatment of patients with chronic cough (Clinical Trial Identifier: NCT03449134 & NCT03449147).
The abstract ‘Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2).’ (ABSTRACT NUMBER: 188) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What are the unmet needs in the treatment of people with refractory or unexplained chronic cough (RCC/UCC)? (0:20)
- How did you assess cough triggers and symptoms among patients with RCC and UCC? (1:35)
- What were the aims and design of the COUGH-1 and COUGH-2 studies, and what were the findings? (2:34)
- What is the mechanism of action of Gefapixant? (3:57)
- How can we use these findings to address the unmet needs of people with chronic cough? (4:55)
Disclosures: Alyn Morice has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Chronic Cough
Analysis of gefapixant efficacy and safety by history of refractory or unexplained chronic cough: Imran Satia, ERS 2023
COUGH 1 and COUGH 2, were randomized, double-blind, placebo-controlled phase 3 trials, that investigated gefapixant for the treatment of refractory or unexplained chronic cough. It was a pleasure to speak with Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) around his analysis of COUGH-1 and -2, looking at gefapixant efficacy by patient history of refractory […]
P2X3 receptor antagonists for the treatment of chronic cough: Imran Satia, ERS 2023
With limited options in the treatment paradigm for refractory or unexplained chronic cough, P2X3 receptor antagonists have shown great promise in clinical trials. We were delighted to speak to Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) to discuss the current unmet needs when treating chronic cough and the investigational P2X3 receptor antagonists currently in […]
Gefapixant for the treatment of chronic cough – a dose-response analysis: Elena Kum, ERS 2023
Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, Hamilton, ON, Canada) around the aims, methodology and findings from her dose-response meta-analysis of gefapixant. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!